Article
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Leukemia - 1 Jan 2017
Versluis J, In 't Hout F E M, Devillier R, van Putten W L J, Manz M G, Vekemans M-C, Legdeur M-C, Passweg J R, Maertens J, Kuball J, Biemond B J, Valk P J M, van der Reijden B A, Meloni G, Schouten H C, Vellenga E, Pabst T, Willemze R, Löwenberg B, Ossenkoppele G, Baron F, Huls G, Cornelissen J J
Abstract excerpt
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with CN-AML in CR1, for whom mutational status of NPM1 and FLT3-ITD was available, including the FLT3-ITD allelic ratio. PRT consisted of reduced intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (alloHSCT)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.